ORPHA:676036
Peritoneal mesothelioma in situ
Publications
3
16.4th percentile
Trials
0
Interventional, condition-specific
Researchers
15
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0971145
- UMLS:C5925102
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3 matched papers (3 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 26 for broader category peritoneal mesothelioma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3
3 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3 in the last 10 years · high confidence · 16.4th percentile (publications denominator)
Phrase hits: 3 · MeSH hits: 0
Who's working on it?
15
Distinct author names in 3 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Churg A2 papers · 2022
Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
Papers in Europe PMC - 02As-Sanie S1 paper · 2022Papers in Europe PMC
- 03Dacic S1 paper · 2020
Department of Pathology University of Pittsburgh, PA, United States. Electronic address: dacics@upmc.edu.
Papers in Europe PMC - 04Fels Elliott DR1 paper · 2022Papers in Europe PMC
- 05Galateau-Salle F1 paper · 2020
Centre National Référent MESOPATH, Centre Leon Berard, Lyon, France.
Papers in Europe PMC - 06Hrycaj SM1 paper · 2022Papers in Europe PMC
- 07Huang T1 paper · 2022Papers in Europe PMC
- 08Johnson ST1 paper · 2022
Division of Thoracic Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Papers in Europe PMC - 09Lieberman RW1 paper · 2022Papers in Europe PMC
- 10Lyons MA1 paper · 2020
Department of Pathology University of Pittsburgh, PA, United States; UPMC Hillman Cancer Center, Shadyside Hospital, Pittsburgh, PA, United States.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 26 trials are registered for peritoneal mesothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
26 interventional trials matched peritoneal mesothelioma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: peritoneal mesothelioma
26
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07330271·RECRUITING·PTC-Guided Therapy for Peritoneal Mesothelioma
Conditions: Peritoneal Mesothelioma·Matched via name phrase
- NCT06057935·RECRUITING·A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Conditions: Malignant Peritoneal Mesothelioma · Peritoneal Mesothelioma · Mesothelioma · Mesothelioma, Malignant·Matched via name phrase
- NCT04847063·RECRUITING·Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Conditions: Peritoneal Mesothelioma · Peritoneal Carcinomatosis · Ovarian Cancer · Gastrointestinal Cancer·Matched via name phrase
- NCT06756035·RECRUITING·CT-95 in Advanced Cancers Associated With Mesothelin Expression
Conditions: Mesothelin-Expressing Tumors · Epithelial Ovarian Cancer · Malignant Pleural Mesothelioma, Advanced · Malignant Peritoneal Mesothelioma, Advanced·Matched via name phrase
- NCT06543069·RECRUITING·Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Conditions: Malignant Peritoneal Mesothelioma, Advanced·Matched via name phrase
- NCT07510815·RECRUITING·Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Conditions: Malignant Pleural Mesotheliomas·Matched via name phrase
- NCT05001880·RECRUITING·Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Conditions: Peritoneal Malignant Mesothelioma·Matched via name phrase
- NCT07277413·RECRUITING·A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Conditions: NSCLC Adenocarcinoma · Gastroesophageal Cancer (GC) · Gastric Adenocarcinoma · Adenocarcinoma of Esophagus·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- isrctn·ISRCTN16171129·No longer recruiting·A randomised Phase II trial to assess whether niraparib is beneficial in patients with mesothelioma that has progressed and been previously treated when compared to the standard of care treatment, termed active symptom control
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Peritoneal mesothelioma in situ — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Peritoneal mesothelioma in situ"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Peritoneal mesothelioma in situ"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"peritoneal mesothelioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T20:26:19.423Z
